This is the initial application of the Baylor College of Medicine Cancer Center (BCMCC) for NCI designation and is being submitted in the 3rd year of an NCI P20 planning grant. Baylor College of Medicine (BCM) is located in the Texas Medical Center (TMC) in Houston, the largest and perhaps most complex medical center in the country with 40 member institutions. Houston is the 4th largest city in the US with a very diverse population. The BCMCC is a consortium cancer center with BCM as the lead partner, and our four hospital affiliates, Texas Children's Hospital, St. Luke's Episcopal Hospital, The DeBakey Veterans Affairs Medical Center, and Ben Taub General Hospital, as formal clinical partners. In addition, as part of a BCM strategy to create its own ambulatory care facilities, the BCMCC is leading the planning for a comprehensive multidisciplinary cancer clinic to be completed in 2008. The BCMCC was formally established in 2002 to integrate the already strong and organized scientific and clinical programs at BCM and our partners, and to create new synergies and programs that take advantage of this unique environment. The unique environment of the TMC creates many opportunities for scientific, clinical, and educational collaborations, of which the BCMCC takes full advantage. The BCMCC has been given the resources and authority to be successful at this task and has made exciting progress over the past three years. It now includes over 260 formal members, and total annual cancer-relevant research funding documented in this proposal approaches $100 million, with close to $40 million coming from the NCI. The 8 research and translational Programs that were organized through the P-20 process remain in place and are growing stronger. These Programs are Cancer Biology, Molecular Carcinogenesis, Nuclear Receptors, Breast Cancer, Cancer Cell and Gene Therapy, Prostate Cancer, Cancer Prevention, and Pediatric Cancer. In addition, although relatively new, the Center has already fostered interactions among its members that have led to several developing research programs including pancreas cancer, genomic instability, and stem cell biology among others. In addition 9 Shared Research Resources are included in this application;6 based on strong-capabilities present at BCM, and 3 (Biostatistics, the Clinical Trials Support Unit, and Pathology and Tissue Banking), created through BCMCC leadership and/or funding. The Center has also established an Office of Outreach and Health Disparities to better translate our extensive research expertise in this area into more coordinated community action among our partners and colleagues in the TMC and the region. Finally, the BCMCC has been recently blessed with a $100 million philanthropic gift from a wonderful Houston family. This gift has been entirely dedicated to support the development of the Center, its programs and its members and to foster collaboration with other institutions. Substantial funds will be available for use in the next year even as a long term endowment is created to ensure future stability. Thus, the CCSG outlines an organizational structure, outstanding leadership, integrated scientific research programs, expert Shared Resources, a process for community outreach, adequate and diverse patient resources, and the institutional support to build an outstanding NCI-designated Cancer Center that will benefit the Houston Community and region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA125123-03S1
Application #
7919836
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
2007-07-01
Project End
2010-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$117,279
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299
Reznik, Ed; Luna, Augustin; Aksoy, Bülent Arman et al. (2018) A Landscape of Metabolic Variation across Tumor Types. Cell Syst 6:301-313.e3
Blue, R Eric; Koushik, Amrita; Engels, Nichlas M et al. (2018) Modulation of alternative splicing of trafficking genes by genome editing reveals functional consequences in muscle biology. Int J Biochem Cell Biol 105:134-143
Dawson, Emily P; Lanza, Denise G; Webster, Nicholas J et al. (2018) Delayed male germ cell sex-specification permits transition into embryonal carcinoma cells with features of primed pluripotency. Development 145:
Freire, Pablo R; Conneely, Orla M (2018) NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBP? and inflammatory signaling. Blood 131:1081-1093
Parikh, Neha; Shuck, Ryan L; Gagea, Mihai et al. (2018) Enhanced inflammation and attenuated tumor suppressor pathways are associated with oncogene-induced lung tumors in aged mice. Aging Cell 17:
Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :
Newton, Jared M; Flores-Arredondo, Jose H; Suki, Sarah et al. (2018) Non-Invasive Radiofrequency Field Treatment of 4T1 Breast Tumors Induces T-cell Dependent Inflammatory Response. Sci Rep 8:3474
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7

Showing the most recent 10 out of 991 publications